Brooks Laboratories

Brooks Laboratories EBIT

The EBIT of Brooks Laboratories (BROOKS.NS) as of Oct 22, 2026 is 54.70 M INR. In the previous year, EBIT was 33.37 M INR — a change of 63.89% (higher).

EBIT

54.70 MINR

YoY

63.89%

Last updated:

In 2026, Brooks Laboratories's EBIT was 54.70 M INR, a 63.89% increase from the 33.37 M INR EBIT recorded in the previous year.

The Brooks Laboratories EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2019
-119.85 M INR
Jan 1, 2020
-89.64 M INR
Jan 1, 2021
-58.95 M INR
Jan 1, 2022
77.38 M INR
Jan 1, 2023
-68.99 M INR
Jan 1, 2024
11.99 M INR
Jan 1, 2025
33.37 M INR
Jan 1, 2026
54.70 M INR
The Brooks Laboratories EBIT history
YEAREBITYoY
54.70 MINR+63.89%
33.37 MINR+178.40%
11.99 MINR-117.38%
-68.99 MINR-189.15%
77.38 MINR-231.26%
-58.95 MINR-34.24%
-89.64 MINR-25.21%
-119.85 MINR-20.78%
-151.30 MINR-412.03%
48.49 MINR-55.18%
108.19 MINR+4.53%
103.50 MINR+36.70%
75.71 MINR-20.99%
95.83 MINR+4.50%
91.70 MINR+25.68%
72.96 MINR+32.92%
54.90 MINR+71.29%
32.05 MINR-18.29%
39.22 MINR+86.85%
20.99 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Brooks Laboratories Revenue

Brooks Laboratories Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
550.30 M INR
-119.85 M INR
-148.05 M INR
Jan 1, 2020
691.33 M INR
-89.64 M INR
-243.76 M INR
Jan 1, 2021
770.68 M INR
-58.95 M INR
-193.76 M INR
Jan 1, 2022
911.85 M INR
77.38 M INR
-193.13 M INR
Jan 1, 2023
624.80 M INR
-68.99 M INR
-209.00 M INR
Jan 1, 2024
794.86 M INR
11.99 M INR
-195.92 M INR
Jan 1, 2025
825.57 M INR
33.37 M INR
-99.67 M INR
Jan 1, 2026
857.38 M INR
54.70 M INR
245.84 M INR

Brooks Laboratories Margins

Brooks Laboratories stock margins

The Brooks Laboratories margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Brooks Laboratories. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Brooks Laboratories.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
17.41 %
-21.78 %
-26.90 %
Jan 1, 2020
22.65 %
-12.97 %
-35.26 %
Jan 1, 2021
28.32 %
-7.65 %
-25.14 %
Jan 1, 2022
-8.68 %
8.49 %
-21.18 %
Jan 1, 2023
20.17 %
-11.04 %
-33.45 %
Jan 1, 2024
28.32 %
1.51 %
-24.65 %
Jan 1, 2025
16.86 %
4.04 %
-12.07 %
Jan 1, 2026
20.95 %
6.38 %
28.67 %

Brooks Laboratories Stock analysis

What does Brooks Laboratories do? Brooks Laboratories Ltd. manufactures pharmaceutical products including Carbapenem category drugs such as Imipenem 250mg + Cilastatin 250mg, Meropenem 125mg, and Doripenem 500mg. The company produces Penicillins in injections, tablets, and dry syrup forms, along with General category products like liquid injections, dry powder injections, and eye/ear drops. Brooks Laboratories markets its pharmaceuticals nationally and internationally to regulated markets through its manufacturing plants in Baddi, Himachal Pradesh. The firm generates revenue by selling these dosage forms to healthcare providers and distributors in regulated pharmaceutical markets. The company's product portfolio includes specific formulations like Iron sucrose 100mg/5ml liquid injections under the General category. Brooks Laboratories targets regulated markets globally for its Carbapenem, Penicillin, and General category products. Its manufacturing operations at Baddi enable nationwide and international distribution of pharmaceuticals. Revenue is derived from the sale of these branded and generic pharmaceutical products to hospitals, pharmacies, and international buyers in compliant markets. Brooks Laboratories focuses on producing injectable and oral dosage forms including tablets, dry syrup, and eye/ear drops. The company's Carbapenem category features Meropenem 1000mg+Tazobactam 500mg and Doripenem 1000mg. Penicillins are available as injections, tablets, and dry syrup. The firm's revenue model relies on direct sales of these pharmaceutical products to healthcare institutions and distributors in regulated markets, ensuring compliance with international pharmaceutical standards. Brooks Laboratories is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Brooks Laboratories's EBIT

Brooks Laboratories's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Brooks Laboratories's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Brooks Laboratories's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Brooks Laboratories’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Brooks Laboratories stock

EBIT of Brooks Laboratories is 54.70 M INR in 2026.

EBIT of Brooks Laboratories changed from 33.37 M INR to 54.70 M INR, representing a 63.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Brooks Laboratories since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Brooks Laboratories historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Brooks Laboratories

All Key Metrics — Brooks Laboratories